Navigating the acquisition of high-purity GHRH analogs requires understanding the chemical synthesis, purity verification, and lot-to-lot analytical testing that dictate laboratory pricing. This guide examines CJC-1295 cost structures, analytical documentation standards, and preclinical mechanisms for scientific institutions.
Navigating the acquisition of high-purity GHRH analogs requires understanding the chemical synthesis, purity verification, and lot-to-lot analytical testing that dictate laboratory pricing. This guide examines CJC-1295 cost structures, analytical documentation standards, and preclinical mechanisms for scientific institutions.
In biomedical research, the cjc price 1295 correlates directly with analytical purity, synthesis methodology, and rigorous quality assurance rather than raw mass alone. High-purity CJC-1295 (both modified GRF 1-29 and DAC variants) typically ranges in price based on sequence length, counterion content, mass spectrometry validation, and endotoxin quantification. Premium research suppliers deliver verified >98% HPLC purity with complete lot traceability.
When evaluating the cjc price 1295 across academic and commercial suppliers, principal investigators must weigh bulk synthesis economics against analytical rigor. Skimping on quality control often results in truncated peptide sequences, residual TFA contamination, or high endotoxin burdens that invalidate sensitive in vitro receptor assays or in vivo animal models.
CJC-1295 is a synthetic 29-amino-acid peptide analog of growth hormone-releasing hormone (GHRH). Originally developed to extend the biological half-life of natural GHRH(1-29), the molecule incorporates four specific amino acid substitutions at positions 2, 8, 15, and 27 (D-Ala, Gln, Ala, and Leu, respectively). This tetrasubstituted structure, frequently referred to as Modified GRF 1-29, confers enhanced resistance to enzymatic cleavage by dipeptidyl peptidase-IV (DPP-IV).
Researchers evaluating compounds on our all-peptides catalog will note that CJC-1295 exists in two distinct chemical configurations: CJC-1295 without DAC (Modified GRF 1-29) and CJC-1295 with Drug Affinity Complex (DAC). The DAC moiety consists of a maleimidopropionic acid linker conjugated to the C-terminal lysine residue. This addition enables covalent binding to endogenous serum albumin via nucleophilic attack on the free Cys34 residue, dramatically altering the pharmacodynamics under study.
The chemical modification directly influences the cost of synthesis. Adding the reactive maleimide linker in CJC-1295 DAC requires extra solid-phase peptide synthesis (SPPS) steps and downstream purification iterations, which is reflected in the overall cjc price 1295 compared to standard modified GRF 1-29 sequences.
In vitro and preclinical animal models demonstrate that CJC-1295 functions as a selective agonist at the growth hormone-releasing hormone receptor (GHRHR), located primarily on somatotropes within the anterior pituitary gland. Activation of GHRHR triggers G-protein-coupled signal transduction, stimulating adenylyl cyclase and increasing intracellular cyclic adenosine monophosphate (cAMP) levels. This cascade promotes calcium influx and the downstream exocytosis of endogenous growth hormone (GH) vesicles.
Unlike native GHRH, which exhibits a plasma half-life of approximately 7 to 12 minutes due to rapid DPP-IV degradation, Modified GRF 1-29 demonstrates enhanced enzymatic stability with a half-life extending past 30 minutes in animal models. When bioconjugated with DAC, preclinical studies suggest the systemic half-life expands up to 6–8 days in rodents and higher mammals due to protected serum albumin transport.
Research focused on somatotrope signaling pathways often investigates how sustained receptor occupancy by CJC-1295 DAC alters pulsatile secretion patterns versus short-acting secretagogues. Investigations published in our research library highlight how these kinetic differences dictate experimental design in cellular and physiological models.
To select the proper research agent, investigators frequently compare CJC-1295 against other GHRH analogs and ghrelin receptor agonists within the growth hormone secretagogue class. A primary point of comparison is Sermorelin, the native 29-amino-acid truncated GHRH sequence. While Sermorelin shares identical target receptors, it lacks the four amino acid substitutions that protect CJC-1295 from rapid DPP-IV breakdown, resulting in a significantly shorter half-life in vitro.
Another distinct class of secretagogues includes growth hormone secretagogue receptor (GHSR-1a) agonists such as Ipamorelin and GHRP-6. While CJC-1295 activates the GHRH receptor, Ipamorelin targets the ghrelin receptor to stimulate somatotropic secretion through a calcineurin-dependent intracellular calcium pathway. Combining a GHRH agonist like CJC-1295 with a GHSR agonist like Ipamorelin is a common model for studying synergistic pituitary stimulation in rodent models.
For specialized metabolic studies, researchers also evaluate Tesamorelin, a 44-amino-acid GHRH analog possessing a trans-3-hexenoic acid group. Comparative studies detailing these distinct mechanisms are accessible through our cjc-1295 dac vs no dac research guide, allowing labs to optimize compound selection according to receptor specificity and biological half-life objectives.
Understanding why the cjc price 1295 varies across suppliers requires examining the core manufacturing workflows of Solid-Phase Peptide Synthesis (SPPS). The synthesis of a 29-amino-acid sequence demands high-grade Fmoc/tBu protected amino acids, specialized coupling reagents (such as HATU or PyBOP), and continuous solvent washing using HPLC-grade DMF. Each added amino acid residue introduces potential side reactions, steric hindrance, and incomplete couplings.
Post-synthesis cleavage using trifluoroacetic acid (TFA) yields crude peptide mixtures containing truncated sequences and deletion peptides. The primary cost driver in high-grade research peptide production is reverse-phase high-performance liquid chromatography (RP-HPLC) purification. Achieving >98% purity requires iterative preparative HPLC runs, which discard substantial fractions of off-target peptide material, directly reducing net yield while escalating production cost.
Furthermore, post-purification processing—including counterion exchange to remove excess toxic TFA, lyophilization cycle optimization, and automated endotoxin reduction—substantially impacts the overall laboratory acquisition cost. Researchers requesting custom quotes or volume allocations via our wholesale portal can review how batch sizing affects unit costs for validated analytical lots.
A low cjc price 1295 is irrelevant if the compound lacks verifiable analytical documentation. Scientific integrity demands that every lot undergo rigorous third-party testing in an ISO 17025 accredited laboratory. PX1 Research mandates that every batch of research peptides includes a comprehensive Certificate of Analysis (COA) detailing identity, purity, and safety metrics.
High-Performance Liquid Chromatography (HPLC) is the gold standard for determining chromatographic purity. The HPLC chromatogram must show a sharp, single primary peak at the designated retention time, with total integrated area under the curve (AUC) demonstrating >98% purity. Broad, split, or tailing peaks signify degradation products, incomplete synthesis fragments, or counterion impurities.
Electrospray Ionization Mass Spectrometry (ESI-MS) confirms exact molecular weight and sequence identity. For CJC-1295 (Modified GRF 1-29), the theoretical monoisotopic mass of C152H252N44O42 is approximately 3367.9 Da. Mass spectrometry reports must display correct m/z charge states (such as [M+3H]3+ or [M+4H]4+) without secondary mass peaks representing truncated sequences. Additionally, Limulus Amebocyte Lysate (LAL) assay testing must verify that bacterial endotoxin levels remain strictly below 0.5 EU/mg.
Proper handling and storage preserve peptide integrity, protecting institutional research investments from premature enzymatic or chemical degradation. Lyophilized CJC-1295 is highly stable when stored in a desiccated environment at -20°C or -80°C, protected from light exposure. Avoid subject-level handling protocols; all handling must strictly follow laboratory safety and reconstitution guidelines.
For reconstitution, research personnel should utilize sterile bacteriostatic water (0.9% benzyl alcohol) or sterile deionized water depending on experimental requirements. Gently direct the solvent down the inner glass wall of the vial rather than shooting directly onto the lyophilized cake. Allow the cake to dissolve naturally or gently swirl the vial; never vortex or vigorously agitate peptide solutions, as mechanical shear forces can cause peptide aggregation and denaturation.
Once reconstituted, aqueous CJC-1295 solutions should be aliquoted into polypropylene microcentrifuge tubes to avoid repeated freeze-thaw cycles, which break peptide bonds and cause loss of bioactivity. Reconstituted aliquots stored at 4°C are stable for short-term experimentation (typically 14–21 days), whereas long-term preservation requires -20°C or lower.
PX1 Research is committed to supplying academic, clinical, and industrial laboratories with uncompromised research compounds. Every lot of CJC-1295 available through our catalog is synthesized in cGMP-compliant facilities within the United States, eliminating the quality volatility associated with unverified overseas sourcing.
We enforce mandatory third-party COA verification for every batch, incorporating RP-HPLC purity analysis, ESI-MS identity confirmation, and quantitative endotoxin testing. Our products, including CJC-1295 No DAC, are backed by fully traceable batch manufacturing records.
To ensure rapid delivery for time-sensitive laboratory protocols, PX1 Research operates dual fulfillment centers in California and Arizona, providing same-day dispatch for orders placed Monday through Friday before 3:00 PM PST. Secure your research supply directly through our online store or contact our institutional sales team for bulk volume inquiries.
What factors directly influence the cjc price 1295 in laboratory supply?
The cjc price 1295 is determined by solid-phase synthesis complexity, sequence length, addition of the DAC linker moiety, iterative RP-HPLC purification runs to achieve >98% purity, TFA counterion exchange, and third-party analytical testing including mass spectrometry and LAL endotoxin assays.
What is the difference between CJC-1295 DAC and CJC-1295 No DAC?
CJC-1295 No DAC (Modified GRF 1-29) consists solely of the 29-amino-acid tetrasubstituted GHRH sequence, offering an extended half-life relative to native GHRH. CJC-1295 DAC includes a maleimidopropionic acid linker conjugated to a C-terminal lysine, enabling covalent binding to circulating serum albumin to extend plasma half-life up to several days in preclinical models.
How should CJC-1295 be stored upon delivery to the lab?
Lyophilized CJC-1295 should be stored at -20°C or -80°C in a dry, dark environment. After reconstitution with sterile bacteriostatic water, liquid aliquots should be refrigerated at 2–8°C for short-term use or frozen at -20°C to prevent degradation. Avoid multiple freeze-thaw cycles.
What purity level is required for CJC-1295 research applications?
In vitro receptor binding assays and in vivo animal research typically require a minimum of 98% HPLC purity. Lower purity peptides contain truncated sequences or synthesis reagents that can alter receptor signaling or induce non-specific cellular responses.
How does PX1 Research verify the purity and identity of CJC-1295?
Every lot of CJC-1295 undergoes independent ISO 17025 lab testing featuring RP-HPLC for chromatographic purity, ESI-MS for molecular mass verification, and LAL assays to confirm endotoxin levels are under 0.5 EU/mg. Certificates of Analysis are publicly available for review.
Can CJC-1295 be combined with Ipamorelin in preclinical models?
Yes, in vitro and preclinical rodent models frequently co-administer GHRH agonists like CJC-1295 with ghrelin receptor agonists like Ipamorelin to investigate synergistic growth hormone release from anterior pituitary somatotropes.
What solvent is recommended for reconstituting CJC-1295 for lab use?
Standard laboratory reconstitution utilizes sterile 0.9% bacteriostatic water or sterile deionized water. The solvent should be added slowly down the vial container wall, followed by gentle swirling without mechanical shaking or vortexing.
Does PX1 Research offer institutional or bulk purchasing options for CJC-1295?
Yes, PX1 Research provides dedicated institutional accounts and wholesale pricing tiers for university, biotechnology, and corporate research laboratories. Inquiries can be submitted via our wholesale department.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.